RxSight reports Q4 revenue down 19% YoY; 2025 net loss $(38.9M); issues weak 2026 guidance

RxSight, Inc.

2025-FY EPS reported -$0.95 revenue$134,479,000

Q4 2025 revenue $32.6M (-19% YoY); LAL revenue -1%, LDD revenue -72%.
FY 2025 revenue $134.5M (-4% YoY); net loss $(38.9M) vs $(27.5M) in 2024.
LAL unit sales 109,615 (+12% YoY); LDD installed base 1,134 units; procedures >300,000 since launch.
FY 2026 guidance: revenue $120-135M (down YoY); gross margin 70-72%; op-ex $150-160M.
Adjusted net loss per share $(0.18) in FY 2025 vs $(0.07) in FY 2024; cash $228.1M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.